Ipamorelin

Ipamorelin is a peptide-selective agonist of growth hormone releasing peptides/growth hormone secretagogue receptors (GHS) and a growth hormone secretagogue.

Ipamorelin is a pentapeptide (AIb-his-D-2-NAL-D-Phit-Lys-NH2) that has shown high GH-releasing potency and efficacy in vitro and in vivo. As a result of a major chemical program, ipamorelin was found in a range of compounds lacking Ala-Trp, the central dipeptide of growth hormone releasing peptide (GHRP) -1.

Ipamorelin, also known as NNC-26-0161, is a a ghrelin mimetic. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Ipamorelin may ameliorate the symptoms in patients with POI. Ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.

Çuňňur hyzmatdaşlygy bolan ýokary hilli önümler we bäsdeşlik bahalary bilen üpjün edip biljek köp sanly ýokary hilli zawodlarymyz bar. Şeýle hem, köpçülikleýin satyn almak üçin arzanladyş berip bileris. Köp hünärli ýük ekspeditor kompaniýalary bilen hyzmatdaşlyk edýäris, önümleri ygtybarly we rahat eliňize berip bileris. Eltip beriş wagty, töleg tassyklanandan 3-20 gün soň.

In vitro experiments, ipamorelin released GH from primary rat pituitary cells with similar efficacy to GHRP-6. Pharmacological analyses using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly show that, like GHRP-6, Ipamorelin /Ipamorelin stimulates GH release through GHRP-like receptors.